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In this issue of the journal, Smith et al. [1] illustrate the
results of a meta-analysis of studies aimed at comparing
the blood pressure effects of different antihypertensive
drugs through use of ambulatory blood pressure mon-
itoring (ABPM). These studies where subdivided into
two groups, according to whether they were based
on a conventional double-blind, placebo-controlled
(DBPC) approach or on the more recently proposed
prospective, randomized, open-label, blinded-endpoint
(PROBE) method [2]. The aim of the paper by Smith et
al. [1] was to assess whether the results of trials on anti-
hypertensive treatment are comparable, in terms of
drug-induced blood pressure reduction, when using a
PROBE rather than the more conventional DBPC
design. The five studies selected (two with the DBPC
design and three with the PROBE design) had a
parallel-group structure and were identified in the con-
text of a clinical programme aimed at evaluating the
features of a specific angiotensin II receptor blocker.
The authors conclude that changes in mean 24-h
ambulatory blood pressure values derived from the
DBPC and PROBE trials included in their meta-analy-
sis are statistically equivalent when the aim is to rule
out a difference of > 3 mmHg in systolic and/or
> 2 mmHg in diastolic blood pressure on comparing the
two drugs. They also conclude that these data support
the validity of a PROBE design in assessing antihyper-
tensive efficacy based on blind ABPM measurements.
Advantages of ABPM in the design of
antihypertensive drug trials
Blood pressure is characterized by high variability, and
a single reading taken at a given time, or even multiple
readings obtained on different days, will only partially
reflect a subject’s mean blood pressure over a whole
day [3,4]. Furthermore, the clinical environment and
the presence of the observer may arouse the subject,
which can lead to an overestimation of blood pressure
if a conventional approach is used [5–7]. ABPM
addresses several of the shortfalls of conventional blood
pressure measurement [8,9] and can be used in clinical
trials to select patients with sustained rather than
isolated office hypertension (also defined as ‘white-coat
hypertension’) [10], to increase the precision in estimat-
ing the effects of blood pressure-lowering drugs, or to
decrease sample size in cross-over trials [11].
Smith et al. [1] emphasize this point, and further
suggest that ABPM limits the need for a control arm in
clinical trials, because mean 24-h ambulatory blood
pressure is minimally affected by placebo.
Whether the blood pressure detected by ambulatory
monitoring is actually influenced by a placebo effect
remains a matter for debate. The issue is important
because it impacts on the design of clinical trials in
hypertension. Some experts [12] argue that ambulatory
monitoring eliminates only observer bias and expecta-
tion and does not remove regression to the mean and
patient-related factors that contribute to the placebo
effect. Other researchers hypothesize that ambulatory
monitoring would make control observations with pla-
cebo redundant [13,14]. If this were true, investigators
making use of ABPM could investigate antihyper-
tensive interventions simply by comparing the blood
pressures before and after administration of a given
treatment. The intra-arterially monitored blood pres-
sure has been shown to remain at a constant level when
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
Editorial comment 1237
0263-6352 & 2003 Lippincott Williams & Wilkins DOI: 10.1097/01.hjh.0000059065.43904.7c
hypertensive patients were administered placebo for
6 weeks [15]. Similarly, in a 6-week study with a non-
invasive recording technique [16], ambulatory blood
pressure fell only slightly during the initial hours of the
recording, and the mean blood pressure over 24-h
remained unaffected. On balance, most publications
favour the view that, over a period of a few weeks, the
ambulatory blood pressure does not decrease with
placebo. However, long-term studies gave different
results [17]. Analysis of the database of the Systolic
Hypertension in Europe trial (Syst-Eur) [18] demon-
strated that, in long-term trials, not accounting for
placebo effects could lead to an overestimation of the
true effects of antihypertensive drugs when using
ABPM. After 1 year of follow-up, the blood pressure
decrease in the placebo arm of the Syst-Eur trial
(n ¼ 169) amounted to 20–40% of the corresponding
change observed under active treatment (n ¼ 168). This
was true both for the conventional and for the ambula-
tory measurements [18]. However, these observations
have to be interpreted cautiously because long-term
changes in blood pressure may be influenced not only
by a placebo effect, but also by other factors such as
changes in lifestyle or intercurrent illnesses.
Whether or not there is a significant placebo effect
when the blood pressure is measured by ambulatory
monitoring is largely an academic discussion in the
context of the multiple and different evaluations that
are performed in a drug trial. Indeed, to evaluate drug
effects other than the blood pressure reduction per se,
such as side-effects or effects on organ damage and
events rate, a control group is always necessary. The
best trial design, in this regard, requires masking both
the patient and the observer. PROBE trials might be
cheaper and simpler than DBPC ones, but are less
precise in this context (see below).
Smith and colleagues also suggest that because of the
greater variability of office blood pressure values com-
pared to ABPM, a larger sample of patients might be
required to have the same power with regard to
statistical inferences concerning blood pressure effects,
when comparing drug-induced changes of office blood
pressure in DBPC and PROBE design studies. This is
certainly the case in cross-over trials [12,13]. However,
by contrast to what is often perceived, the advantage of
the higher reproducibility of ambulatory blood pressure
is lost in trials with a parallel-group design [11], such as
those selected for this meta-analysis. Reducing the
sample size is also not possible when the aim of a study
is to investigate the effects of an antihypertensive agent
on the diurnal profile of blood pressure [11].
However, in spite of these problems, Smith et al. [1] are
correct when they emphasize that a PROBE design
could be considered only when focusing on ‘objective’
blood pressure determination. As they point out in their
paper, comparing the drug-induced blood pressure
changes in DBPC and PROBE design studies by means
of office blood pressure measurements would hardly be
acceptable because focusing on office blood pressure
readings would mean lacking any blinded endpoint,
this would imply that physician’s and patient’s biases
cannot be eliminated. Finally, use of office blood
pressure readings would not allow the comparison
between the information provided by these two ap-
proaches on the degree of blood pressure control over
24 h, the daytime and the night-time. In particular,
focus on office blood pressure readings only would
prevent any comparison of the ability of these different
methods to assess drug-induced changes in hourly
blood pressure profiles, in blood pressure overall varia-
bility or in the degree of morning blood pressure surge
[19]. This would also be the case when the time
distribution of the antihypertensive effect is investi-
gated by assessing the duration of action of a given
compound, and the homogeneity of its blood pressure
lowering action over 24 h, through the use of mathema-
tical indices such as the trough-to-peak ratio or the
smoothness index [20–22].
Double-blind, placebo-controlled versus
prospective, open-label, blinded-endpoint
study design
Properly designed, randomized, double-blind, placebo-
controlled (DBPC) trials are presently regarded as the
‘gold standard’ in the field of clinical studies aimed at
evaluating antihypertensive drug efficacy. This is re-
flected by the fact that regulatory authorities in several
countries, as well as at the international level, require
evidence of efficacy or safety from DBPC trials for
antihypertensive drug registration or approval purposes
[23]. However, as pointed our by Smith et al. [1], DBPC
trials have some disadvantages [1]. They have a high
cost and are time-consuming both for the hospital staff
involved, as well as for the recruited patients. Moreover,
physicians and/or their patients may be reluctant to
accept the possibility of a prolonged period of blind
treatment, particularly if the control is placebo or if the
recruited patients are characterized by an increased
cardiovascular risk profile. PROBE design studies do not
share these difficulties and may thus appear as a simpler,
cheaper and more attractive alternative in several in-
stances, in particular when applied to studies taking
advantage of all the positive features of ABPM. PROBE
design studies may offer the possibility of an unbiased
data collection only when changes in objectively deter-
mined endpoints (e.g. automated blood pressure meas-
urements) are considered however. This is certainly not
the case when collecting information on treatment side-
effects, as well as when assessing the impact of treat-
ment on organ damage or events rate. Indeed, the
blinded validation of disease outcomes in open trials
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
1238 Journal of Hypertension 2003, Vol 21 No 7
does not rule out the possibility that prior knowledge of
treatment allocation results in selective over- or under-
reporting of events, as well as in biased detection of
organ damage changes. This might explain why rates of
common side-effects to major drug classes are usually
twice as high in open compared to double-blind trials.
Moreover, a PROBE design may be affected by selec-
tion bias when recruiting patients. Although, theoreti-
cally, this should not occur because a randomization
process is implemented aimed at preventing this incon-
venience, the open design features of PROBE might
expose local investigators to the influence of the clinical
information they have access to, thus interfering with a
truly blinded randomization of patients.
Finally, some caution in concluding on the correspon-
dence between DBPC and PROBE design trials is also
suggested by the peculiar selection of studies included
in the meta-analysis by Smith et al. [1], who focus on
data obtained from a clinical database built when
comparing the properties of a specific angiotensin II
receptor blocker with those of other drugs. This was
carried out by considering studies that are not always
strictly comparable in the subjects’ selection criteria,
duration of data collection and previous antihyperten-
sive drug regimens. Moreover, the question of whether
the authors’ results would be confirmed when consider-
ing studies carried out according to different methodo-
logical approaches (e.g. by using automated self-blood
pressure monitoring at home) remains unaddressed.
In conclusion, the study by Smith et al. [1] appears to
offer an interesting contribution to the discussion on the
methodology of drug trials, and provides evidence that
DBPC and PROBE design studies offer similar informa-
tion on ambulatory blood pressure reduction in trials
aimed at comparing different antihypertensive drugs.
However, their results should not lead to the more
generalized conclusion that DBPC and PROBE design
studies are to be considered as largely equivalent when
organizing antihypertensive drug trials. By contrast,
there are several instances when a double-blind, place-
bo-controlled approach still appears to be necessary.
This is the case when collecting data on the effects of
drugs on parameters other than the objective information
represented by automated, computerized ambulatory
blood pressure measurements, such as changes in clinic
blood pressure, side-effects and other clinical endpoints.
Furthermore, this is also the case when a true blinded
randomization of recruited subjects has to be enforced.
Therefore, caution and great methodological care are
needed when the decision to adopt a PROBE design is
taken, even when the trial initially appears to be
focused only on blindly and objectively determined
endpoints.
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